The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Morningstar brands and products Company Portfolio ...

However, several key assets, including TEVA's movement disorder therapy Austedo, its new schizophrenia drug Uzedy, and the company's generic portfolio, offset the impact. Revenue from Austedo ...

The decline was partially offset by higher revenues from generic products globally and strong growth from branded drugs, Austedo, Ajovy and Uzedy, along with the sale of certain product rights.

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Teva 2024 Results earnings conference call today at 8:00am ET, webcast and replay: https://events.q4inc.com/attendee/899170090 * NDA (New Drug Application): Formal ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies ...